Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women

Journal of Bone and Mineral Metabolism

Volumn 33, Issue 2, 2015, Pages 207-212

  Hegazy, Sahar Kamal ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Diabetes; Metformin; Osteoporosis; Postmenopause; Sitagliptin

Indexed keywords

ALKALINE PHOSPHATASE; AMINO ACID; ANTIDIABETIC AGENT; DEOXYPYRIDINOLINE; METFORMIN; OSTEOCALCIN; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE;

AGED; BLOOD; BONE; BONE DENSITY; BONE DEVELOPMENT; DIABETES MELLITUS; DRUG EFFECTS; FEMALE; HUMAN; LUMBAR VERTEBRA; METABOLIC BONE DISEASE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE; PROCEDURES; URINE;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LUMBAR VERTEBRAE; METFORMIN; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PYRAZINES; TRIAZOLES;

EID: 84895914612     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-014-0581-y     Document Type: Article

References (36)

1. Schwartz AV (2003) Diabetes mellitus: does it affect bone? Calcif Tissue Int 73:515–519
2. Inzerillo AM, Epstein S (2004) Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 5:261–268
3. Leidig-Bruckner G, Ziegler R (2001) Diabetes mellitus—a risk for osteoporosis? Exp Clin Endocrinol Diabetes 109:S493–S514
4. Nicodemus KK, Folsom AR (2001) Iowa Women’s health study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192–1197
5. Cheng AY, Fantus IG (2005) Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172:213–226
6. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L (2006) Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 536:38–46
7. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375:414–419
8. Jang WG, Kim EJ, Bae IH, Lee KN, Kim YD, Kim DK, Kim SH, Lee CH, Franceschi RT, Choi HS, Koh JT (2011) Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 48:885–893
9. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, Korbonits M, Chenu CC (2010) AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 47:309–319
10. Zhen D, Chen Y, Tang X (2010) Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complicat 24:334–344
11. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C (2010) Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 25:211–221
12. Wu W, Ye Z, Zhou Y, Tan WS (2011) AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells. Int J Artif Organs 34:1128–1136
13. Kasai T, Bandow K, Suzuki H, Chiba N, Kakimoto K, Ohnishi T, Kawamoto S, Nagaoka E, Matsuguchi T (2009) Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol 221:740–749
14. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-likepeptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616–619. doi:10.1172/JCI112855
15. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262–269. doi:10.1038/nrendo.2009.48
16. Martin JH, Deacon CF, Gorrell MD, Prins JB (2011) Incretin-based therapies: review of the physiology, pharmacology and emerging clinical experience. Int Med J 41:299–307. doi:10.1111/j.1445-5994.2011.02439.x
17. Marchetti P, Lupi R, Ugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D’Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, Dotta F (2012) A local glucagon-likepeptide1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262–3272. doi:10.1007/s00125-012-2716-9
18. Hamann C, Kirschner S, Gün-ther KP, Hofbauer LC (2012) Bone, sweet bone–osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol 8:297–305. doi:10.1038/nrendo.2011.233
19. Kaplan A (1984) Glucose. Clin Chem 30:1032–1036
20. Trivelli L, Ranney H, Lai H (1971) Hemoglobin components in patients with diabetes mellitus. New Engl J Med 284:353–356
21. Kind PRN, King EJ (1954) Estimation of plasma phosphatase by determination of hydrolyzed phenol with amino-antipyrine. J Clin Pathol 7:322–326
22. Jeyabalan J, Viollet B, Smitham P, Ellis SA, Zaman G, Bardin C, Goodship A, Roux JP, Pierre M, Chenu C (2013) The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 24:2659–2670. doi:10.1007/s00198-013-2371-0
23. Gao Y, Li Y, Xue J, Jia Y, Hu J (2010) Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 635:231–236. doi:10.1016/j.ejphar.2010.02.051
24. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, Bai XC (2011) Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 112:2902–2909. doi:10.1002/jcb.23206
25. Tolosa MJ, Chuguransky SR, Sedlinsky C, Schurman L, McCarthy AD, Molinuevo MS, Cortizo AM (2013) Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin. Diabetes Res Clin Pract 101:177–186. doi:10.1016/j.diabres.2013.05.016
26. Wang C, Li H, Chen SG, He JW, Sheng CJ, Cheng XY, Qu S, Wang KS, Lu ML, Yu YC (2012) The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. J Bone Miner Metab 30:630–637. doi:10.1007/s00774-012-0374-0
27. Salai M, Somjen D, Gigi R, Yakobson O, Katzburg S, Dolkart O (2013) Effects of commonly used medications on bone tissue mineralization in SaOS-2 human bone cell line: an in vitro study. Bone Joint J 95:1575–1580. doi:10.1302/0301-620X.95B11.31158
28. Chailurkit LO, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R (2001) Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 47:1083–1088
29. Watts NB (1999) Clinical utility of biochemical markers of bone remodeling. Clin Chem 45:1359–1368
30. Chakhtoura M, Azar ST (2013) Incretin based therapies: bone protective effects. Endocr Metab Immune Disord Drug Targets 13(4):289–294
31. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Peñacarrillo ML (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84:453–461. doi:10.1007/s00223-009-9220-3
32. Hayakawa N, Suzuki A (2012) Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture. Clin Calcium 22:1383–1390 (pii:CliCa120913831390)
33. Yamada Y (2012) Diabetes mellitus and osteoporosis. Incretin as a coordinator of glucose and bone metabolism. Clin Calcium 22:1353–1358 (pii:CliCa120913531358)
34. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y et al (2012) Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 4:309–313
35. Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 28:1641–1652. doi:10.1002/jbmr.1898
36. Bunck MC, Poelma M, Eekhoff EM, Schweizer A, Heine RJ, Nijpels G, Foley JE, Diamant M (2012) Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 4:181–185. doi:10.1111/j.1753-0407.2011.00168.x